Who are Xueshuanxinmaining tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Entecavir + Fuzheng Huayu Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xueshuanxinmaining-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Xueshuanxinmaining tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xueshuanxinmaining tablet (Xueshuanxinmaining tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine formulation. Area: Cardiovascular.

marketed Traditional Chinese medicine formulation Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Xueshuanxinmaining tablet (Xueshuanxinmaining tablet) — Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Xueshuanxinmaining tablet improves blood circulation and reduces blood stasis through traditional Chinese medicine principles.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xueshuanxinmaining tablet TARGET	Xueshuanxinmaining tablet	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine formulation
Entecavir + Fuzheng Huayu Tablet	Entecavir + Fuzheng Huayu Tablet	ShuGuang Hospital	marketed	Nucleoside reverse transcriptase inhibitor (entecavir component); traditional Chinese medicine formulation (Fuzheng Huayu component)	HBV polymerase/reverse transcriptase (entecavir); multiple targets including hepatic stellate cells and inflammatory pathways (Fuzheng Huayu)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine formulation class)

Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xueshuanxinmaining tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/xueshuanxinmaining-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab